The wearable cardioverter-defibrillator vest: Indications and ongoing questions Article

Full Text via DOI: 10.1016/j.pcad.2019.05.005 PMID: 31077726 Web of Science: 000474940300009
International Collaboration

Cited authors

  • Sandhu, Uday; Rajyaguru, Chirag; Cheung, Christopher C.; Morin, Daniel P.; Lee, Byron K.


  • Multiple clinical trials have demonstrated the efficacy of implantable cardioverter-defibrillators (ICDs) for the prevention of sudden cardiac death (SCD) among specific high-risk populations. However, it remains unclear how to optimally treat those patients who are at elevated risk of cardiac arrest but are not among the presently identified groups proven to benefit from an ICD, are unable to tolerate surgical device implantation, or refuse invasive therapies. The wearable cardioverter-defibrillator (WCD) is an alternative antiarrhythmic device that provides continuous cardiac monitoring and defibrillation capabilities through a noninvasive, electrode-based system. The WCD has been shown to be highly effective at restoration of sinus rhythm in patients with a ventricular tachyarrhythmia, and one randomized trial using the WCD in patients with recent myocardial infarction at elevated risk for arrhythmic death reported a decrease in overall mortality despite no SCD mortality benefit. The current clinical indications for WCD use are varied and continue to evolve as experience with this technology increases. (C) 2019 Elsevier Inc. All rights reserved.

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0033-0620

Start page

  • 256

End page

  • 264


  • 62


  • 3